These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21816053)

  • 1. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
    Spooner AM; Deegan C; D'Arcy DM; Gowing CM; Donnelly MB; Corrigan OI
    BMC Clin Pharmacol; 2011 Aug; 11():11. PubMed ID: 21816053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
    D'Arcy DM; Casey E; Gowing CM; Donnelly MB; Corrigan OI
    BMC Pharmacol Toxicol; 2012 Nov; 13():14. PubMed ID: 23136834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration.
    Wallis SC; Mullany DV; Lipman J; Rickard CM; Daley PJ
    Intensive Care Med; 2001 Apr; 27(4):665-72. PubMed ID: 11398692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.
    Roger C; Wallis SC; Louart B; Lefrant JY; Lipman J; Muller L; Roberts JA
    J Antimicrob Chemother; 2016 Jun; 71(6):1643-50. PubMed ID: 26957490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.
    DelDot ME; Lipman J; Tett SE
    Br J Clin Pharmacol; 2004 Sep; 58(3):259-68. PubMed ID: 15327585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.
    Roger C; Muller L; Wallis SC; Louart B; Saissi G; Lipman J; Lefrant JY; Roberts JA
    J Antimicrob Chemother; 2016 Feb; 71(2):464-70. PubMed ID: 26538503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
    Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
    Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.
    Malone ME; Corrigan OI; Kavanagh PV; Gowing C; Donnelly M; D'Arcy DM
    Int J Antimicrob Agents; 2013 Oct; 42(4):335-42. PubMed ID: 23920093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
    Guenter SG; Iven H; Boos C; Bruch HP; Muhl E
    Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
    Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Levkovich BJ; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Roberts JA; Shekar K; Fraser JF;
    Anaesth Crit Care Pain Med; 2022 Jun; 41(3):101080. PubMed ID: 35472580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
    Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
    J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.
    Fish DN; Teitelbaum I; Abraham E
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2421-8. PubMed ID: 15917542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.